|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,506.00 GBX | -0.78% |
|
-0.63% | +29.02% |
| 08:29pm | GSK wins US approval for twice-yearly asthma drug | RE |
| 12-16 | European Equities Close Mostly Lower in Tuesday Trading; Eurozone Business Activity Rises Every Month in 2025 | MT |
| Capitalization | 281B 239B 223B 209B 387B 25,566B 424B 2,610B 1,007B 12,011B 1,055B 1,033B 43,537B | P/E ratio 2025 * |
27.3x | P/E ratio 2026 * | 23.6x |
|---|---|---|---|---|---|
| Enterprise value | 303B 257B 240B 225B 416B 27,517B 456B 2,809B 1,084B 12,927B 1,135B 1,112B 46,859B | EV / Sales 2025 * |
5.17x | EV / Sales 2026 * | 4.76x |
| Free-Float |
96.62% | Yield 2025 * |
1.78% | Yield 2026 * | 1.88% |
Last Transcript: AstraZeneca PLC
| 1 day | -0.78% | ||
| 1 week | -0.63% | ||
| Current month | -3.35% | ||
| 1 month | -0.19% | ||
| 3 months | +19.04% | ||
| 6 months | +24.85% | ||
| Current year | +29.02% |
| 1 week | 13,362 |  | 13,836 |
| 1 month | 13,362 | | 14,206 |
| Current year | 9,573.5 | | 14,206 |
| 1 year | 9,573.5 | | 14,206 |
| 3 years | 9,461 | | 14,206 |
| 5 years | 6,736 | | 14,206 |
| 10 years | 3,680 | | 14,206 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 2021-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 2023-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 64 | 2017-04-26 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 8.29% | 62 M€ | +14.88% | - |
| 5.39% | 1,412 M€ | +0.17% | - |
| 5.17% | 26 M€ | +10.71% | - |
| 4.89% | 787 M€ | +15.49% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.78% | -0.63% | +28.34% | +21.06% | 282B | |
| -0.74% | +7.34% | +35.34% | +192.96% | 951B | |
| -2.27% | +4.67% | +45.50% | +19.14% | 516B | |
| -1.66% | +0.30% | +30.32% | +39.38% | 402B | |
| -0.47% | +1.62% | +25.01% | +6.32% | 346B | |
| +0.22% | +0.62% | +22.14% | +27.59% | 259B | |
| -1.98% | +1.42% | -1.79% | -10.01% | 249B | |
| -2.23% | +3.39% | -60.20% | -33.31% | 221B | |
| +0.44% | +4.11% | +22.60% | +22.19% | 175B | |
| -3.41% | +0.79% | +1.11% | -50.33% | 150B | |
| Average | -0.83% | +2.57% | +14.84% | +23.50% | 355.18B | |
| Weighted average by Cap. | -0.69% | +3.50% | +23.09% | +59.40% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 58.58B 49.75B 46.54B 43.63B 80.52B 5,326B 88.25B 544B 210B 2,502B 220B 215B 9,069B | 62.31B 52.92B 49.5B 46.4B 85.64B 5,664B 93.87B 578B 223B 2,661B 234B 229B 9,646B |
| Net income | 10.35B 8.79B 8.22B 7.71B 14.23B 941B 15.59B 96.06B 37.06B 442B 38.82B 38.01B 1,602B | 12.02B 10.21B 9.55B 8.95B 16.52B 1,092B 18.1B 112B 43.03B 513B 45.07B 44.13B 1,860B |
| Net Debt | 21.46B 18.22B 17.05B 15.98B 29.49B 1,951B 32.32B 199B 76.83B 916B 80.48B 78.8B 3,322B | 15.36B 13.05B 12.21B 11.44B 21.12B 1,397B 23.14B 143B 55.01B 656B 57.62B 56.42B 2,378B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-16 | 13,506.00 p | -0.78% | 3,264,200 |
| 25-12-15 | 13,612.00 p | +1.25% | 2,467,870 |
| 25-12-12 | 13,444.00 p | -1.12% | 1,443,781 |
| 25-12-11 | 13,596.00 p | +0.61% | 1,284,701 |
| 25-12-10 | 13,514.00 p | -0.57% | 2,485,928 |
Delayed Quote London S.E., December 16, 2025 at 11:35 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition